Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00266669 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon
A Phase 3 study, sponsored by MediQuest Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00266669 is a Phase 3 study that has completed, run by MediQuest Therapeutics. The registered enrollment target is 200 participants.
The verdict
NCT00266669, a Phase 3 study, has completed, sponsored by MediQuest Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy and safety of a topical gel formulation of nitroglycerin, in comparison to a matching placebo, for patients with moderate to severe primary Raynaud's phenomenon or patients with Raynaud's phenomenon secondary to autoimmune diseases, such as scleroderma.
Interventions
- DRUG Topical organogel with nitroglycerin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00266669
The ClinicalTrials.gov registry entry for NCT00266669 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MediQuest Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topical organogel with nitroglycerin is the first listed.
NCT00266669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00266669 about?
NCT00266669 is a clinical study titled "Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon". The purpose of this study is to investigate the efficacy and safety of a topical gel formulation of nitroglycerin, in comparison to a matching placebo, for patients with moderate to severe primary Raynaud's phenomenon or patients with Raynaud's phenomenon secondary to autoimmune diseases, such as sc...
What is the current status of trial NCT00266669?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2005-12. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00266669?
The interventions under investigation include: Topical organogel with nitroglycerin (DRUG).
Who is sponsoring clinical trial NCT00266669?
This trial is sponsored by MediQuest Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.